Shigellosis Market

Market Overview:

The shigellosis market reached a value of USD 112.7 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 273.8 Million by 2035, exhibiting a growth rate (CAGR) of 8.44% during 2025-2035.

The shigellosis market has been comprehensively analyzed in IMARC's new report titled "Shigellosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Shigellosis is a bacterial infection that affects the digestive tract. It is caused by the Shigella bacteria. Shigella bacteria can be transferred by contaminated water and food, as well as through contact with contaminated feces. The bacteria produce toxins that irritate the intestines, resulting in the major indication of diarrhea. Symptoms typically appear one to two days after exposure and include diarrhea with slimy-consistent stools, fever, abdominal pain, and the need to evacuate feces even when the intestines are empty. The diarrhea could be bloody. Symptoms normally last five to seven days, and it can take several months before bowel habits return completely to normal. Diagnosing shigellosis commonly involves a comprehensive clinical assessment and physical examination. The healthcare provider may also conduct a stool culture procedure to identify and isolate Shigella bacteria, which are then tested for antibiotic susceptibility. In some cases, Ova and parasite stool studies may be performed to confirm the diagnosis and rule out numerous other causes of infectious diarrhea.

The escalating prevalence of poor sanitation and hygiene practices, such as inadequate handwashing and improper disposal of sewage, which can contribute to the spread of Shigella, is primarily driving the shigellosis market. In addition to this, the inflating utilization of effective antibiotics, like ciprofloxacin, azithromycin, and ceftriaxone, to shorten the duration of the illness and reduce the period of Shigella excretion, is also creating a positive outlook for the market. Moreover, the widespread adoption of polymerase chain reaction (PCR) technique, which can detect Shigella DNA in stool samples, thereby offering a faster and more sensitive diagnostic method compared to traditional culture, is further bolstering the market growth. Apart from this, the rising usage of oral rehydration therapy, since it works by preventing and treating dehydration through the consumption of a balanced solution containing glucose and electrolytes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized treatment that tailors antibiotic therapy based on patient demographics and specific resistance patterns to enhance efficacy, is expected to drive the shigellosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the shigellosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for shigellosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the shigellosis market in any manner.

Recent Developments:

• In October 2024, Valneva SE and LimmaTech Biologics AG announced that Shigella4V (S4V), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, had received Fast Track designation from the U.S. FDA, for which Valneva had obtained an exclusive worldwide license from LimmaTech.

Drugs:

Shigella4V is a tetravalent bioconjugate vaccine developed to prevent shigellosis, an infection caused by Shigella bacteria. It comprises O-antigen polysaccharides from the four most prevalent Shigella serotypes, each covalently linked to a carrier protein. This design prompts the immune system to recognize these bacterial components, leading to the production of specific antibodies. Upon subsequent exposure to Shigella, these antibodies facilitate rapid identification and neutralization of the bacteria, thereby preventing infection.

ShigaShield, developed by Intralytix, is a bacteriophage-based antimicrobial designed to target and eliminate Shigella species, the bacteria responsible for shigellosis. ShigaShield specifically infects and lyses pathogenic Shigella strains, including S. flexneri, S. sonnei, and S. dysenteriae. Upon application to contaminated foods or environments, these bacteriophages bind to their bacterial hosts, inject their genetic material, and replicate within the bacteria, leading to bacterial cell lysis and a reduction in Shigella contamination.

Tebipenem pivoxil is a carbapenem, a class of antibiotics known for their broad-spectrum activity against Gram-negative bacteria, including Shigella. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. This inhibition prevents the formation of a functional bacterial cell wall, leading to cell lysis (rupture) and ultimately bacterial death. Tebipenem pivoxil is designed to resist degradation by beta-lactamases, enzymes that bacteria produce to inactivate beta-lactam antibiotics, thus enhancing its effectiveness against a broader range of bacteria.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the shigellosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the shigellosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current shigellosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the shigellosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the shigellosis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the shigellosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of shigellosis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of shigellosis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of shigellosis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with shigellosis across the seven major markets?
• What is the size of the shigellosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of shigellosis?
• What will be the growth rate of patients across the seven major markets?

Shigellosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for shigellosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the shigellosis market?
• What are the key regulatory events related to the shigellosis market?
• What is the structure of clinical trial landscape by status related to the shigellosis market?
• What is the structure of clinical trial landscape by phase related to the shigellosis market?
• What is the structure of clinical trial landscape by route of administration related to the shigellosis market?